FDA requirements for the study of endorphins

Tocus, Edward C.

doi:10.1007/978-1-349-04015-5_45

Edward C. Tocus⁴

211 Accesses

Abstract

This chapter will discuss the conditions which the U.S. Food and Drug Administration (FDA) will require for the study of the endorphins in man.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

eBook: USD 16.99; Price excludes VAT (USA)

Softcover Book: USD 109.99; Price excludes VAT (USA)

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Author information

Authors and Affiliations

Division of Neuropharmacological Drug Products, Bureau of Drugs, U.S. Food and Drug Administration, USA
Edward C. Tocus

Authors

Edward C. Tocus
View author publications
You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

National Institute of Mental Health, Parklawn Building, 20857, Rockville, Maryland, USA
Earl Usdin Ph.D.
National Institute of Mental Health, Bethesda, Maryland, USA
William E. Bunney Jr. M.D.
Rockland Research Center, 10962, Orangeburg, New York, USA
Nathan S. Kline M.D.

Copyright information

About this chapter

Cite this chapter

Tocus, E.C. (1979). FDA requirements for the study of endorphins. In: Usdin, E., Bunney, W.E., Kline, N.S. (eds) Endorphins in Mental Health Research. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-04015-5_45

Download citation

DOI: https://doi.org/10.1007/978-1-349-04015-5_45
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-04017-9
Online ISBN: 978-1-349-04015-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)

Publish with us

Policies and ethics